Bulk Manufacturer of Controlled Substances Registration, 27658-27659 [2019-12504]
Download as PDF
<![CDATA[
khammond on DSKBBV9HB2PROD with NOTICES
27658
Federal Register / Vol. 84, No. 114 / Thursday, June 13, 2019 / Notices
Act of 1930 (19 U.S.C. 1673d(b)), as a
result of an affirmative preliminary
determination by Commerce that
imports of mattresses from China are
being sold in the United States at less
than fair value within the meaning of
section 733 of the Act (19 U.S.C. 1673b).
The investigation was requested in a
petition filed on September 18, 2018, by
Corsicana Mattress Company, Dallas,
Texas; Elite Comfort Solutions,
Newman, Georgia; Future Foam Inc.,
Council Bluffs, Iowa; FXI, Inc. Media,
Pennsylvania; Innocor, Inc., Red Bank,
New Jersey; Kolcraft Enterprises Inc.,
Chicago, Illinois; Leggett & Platt,
Incorporated, Carthage, Missouri; Serta
Simmons Bedding, LLC, Atlanta,
Georgia; and Tempur Sealy
International, Inc., Lexington, Kentucky.
For further information concerning
the conduct of this phase of the
investigation, hearing procedures, and
rules of general application, consult the
Commission’s Rules of Practice and
Procedure, part 201, subparts A and B
(19 CFR part 201), and part 207,
subparts A and C (19 CFR part 207).
Participation in the investigation and
public service list.—Persons, including
industrial users of the subject
merchandise and, if the merchandise is
sold at the retail level, representative
consumer organizations, wishing to
participate in the final phase of this
investigation as parties must file an
entry of appearance with the Secretary
to the Commission, as provided in
section 201.11 of the Commission’s
rules, no later than 21 days prior to the
hearing date specified in this notice. A
party that filed a notice of appearance
during the preliminary phase of the
investigation need not file an additional
notice of appearance during this final
phase. The Secretary will maintain a
public service list containing the names
and addresses of all persons, or their
representatives, who are parties to the
investigation.
Limited disclosure of business
proprietary information (BPI) under an
administrative protective order (APO)
and BPI service list.—Pursuant to
section 207.7(a) of the Commission’s
rules, the Secretary will make BPI
gathered in the final phase of this
investigation available to authorized
applicants under the APO issued in the
investigation, provided that the
application is made no later than 21
days prior to the hearing date specified
in this notice. Authorized applicants
must represent interested parties, as
defined by 19 U.S.C. 1677(9), who are
parties to the investigation. A party
granted access to BPI in the preliminary
phase of the investigation need not
reapply for such access. A separate
VerDate Sep<11>2014
16:55 Jun 12, 2019
Jkt 247001
service list will be maintained by the
Secretary for those parties authorized to
receive BPI under the APO.
Staff report.—The prehearing staff
report in the final phase of this
investigation will be placed in the
nonpublic record on September 19,
2019, and a public version will be
issued thereafter, pursuant to section
207.22 of the Commission’s rules.
Hearing.—The Commission will hold
a hearing in connection with the final
phase of this investigation beginning at
9:30 a.m. on Thursday, October 10,
2019, at the U.S. International Trade
Commission Building. Requests to
appear at the hearing should be filed in
writing with the Secretary to the
Commission on or before October 4,
2019. A nonparty who has testimony
that may aid the Commission’s
deliberations may request permission to
present a short statement at the hearing.
All parties and nonparties desiring to
appear at the hearing and make oral
presentations should participate in a
prehearing conference to be held on
October 8, 2019, at the U.S.
International Trade Commission
Building, if deemed necessary. Oral
testimony and written materials to be
submitted at the public hearing are
governed by sections 201.6(b)(2),
201.13(f), and 207.24 of the
Commission’s rules. Parties must submit
any request to present a portion of their
hearing testimony in camera no later
than 7 business days prior to the date of
the hearing.
Written submissions.—Each party
who is an interested party shall submit
a prehearing brief to the Commission.
Prehearing briefs must conform with the
provisions of section 207.23 of the
Commission’s rules; the deadline for
filing is September 26, 2019. Parties
may also file written testimony in
connection with their presentation at
the hearing, as provided in section
207.24 of the Commission’s rules, and
posthearing briefs, which must conform
with the provisions of section 207.25 of
the Commission’s rules. The deadline
for filing posthearing briefs is October
17, 2019. In addition, any person who
has not entered an appearance as a party
to the investigation may submit a
written statement of information
pertinent to the subject of the
investigation, including statements of
support or opposition to the petition, on
or before October 17, 2019. On
November 5, 2019, the Commission will
make available to parties all information
on which they have not had an
opportunity to comment. Parties may
submit final comments on this
information on or before November 7,
2019, but such final comments must not
PO 00000
Frm 00080
Fmt 4703
Sfmt 4703
contain new factual information and
must otherwise comply with section
207.30 of the Commission’s rules. All
written submissions must conform with
the provisions of section 201.8 of the
Commission’s rules; any submissions
that contain BPI must also conform with
the requirements of sections 201.6,
207.3, and 207.7 of the Commission’s
rules. The Commission’s Handbook on
E-Filing, available on the Commission’s
website at https://edis.usitc.gov,
elaborates upon the Commission’s rules
with respect to electronic filing.
Additional written submissions to the
Commission, including requests
pursuant to section 201.12 of the
Commission’s rules, shall not be
accepted unless good cause is shown for
accepting such submissions, or unless
the submission is pursuant to a specific
request by a Commissioner or
Commission staff.
In accordance with sections 201.16(c)
and 207.3 of the Commission’s rules,
each document filed by a party to the
investigation must be served on all other
parties to the investigation (as identified
by either the public or BPI service list),
and a certificate of service must be
timely filed. The Secretary will not
accept a document for filing without a
certificate of service.
Authority: This investigation is being
conducted under authority of title VII of the
Tariff Act of 1930; this notice is published
pursuant to section 207.21 of the
Commission’s rules.
By order of the Commission.
Issued: June 7, 2019.
Katherine Hiner,
Supervisory Attorney.
[FR Doc. 2019–12434 Filed 6–12–19; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Registration
ACTION:
Notice of registration.
The registrant listed below
has applied for and been granted a
registration by the Drug Enforcement
Administration (DEA) as a bulk
manufacturer of a basic class of
schedule II controlled substances.
SUPPLEMENTARY INFORMATION: The
company listed below applied to be
registered as a bulk manufacturer of a
basic class of schedule II controlled
substances. Information on a previously
published notice is listed below. No
SUMMARY:
E:\FR\FM\13JNN1.SGM
13JNN1
27659
Federal Register / Vol. 84, No. 114 / Thursday, June 13, 2019 / Notices
comments or objections were submitted
for the notice.
Company
FR docket
Navinta, LLC ...............
84 FR 5498
Published
February 21, 2019.
The DEA has considered the factors in
21 U.S.C. 823(a) and determined that
the registration of this registrant to
manufacture the applicable basic class
of controlled substances is consistent
with the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. The DEA
investigated the company’s maintenance
of effective controls against diversion by
inspecting and testing the company’s
physical security systems, verifying the
company’s compliance with state and
local laws, and reviewing the company’s
background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the DEA has granted a
registration as a bulk manufacturer to
the above listed company.
Dated: June 3, 2019.
John J. Martin,
Assistant Administrator.
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
ADDRESSES:
[FR Doc. 2019–12504 Filed 6–12–19; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: Sigma Aldrich
Research
ACTION:
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before August 12, 2019.
DATES:
Notice of application.
In
accordance with 21 CFR 1301.33(a), this
is notice that on March 7, 2019, Sigma
Aldrich Research, Biochemicals, Inc.,
400–600 Summit Drive, Burlington,
Massachusetts 01803 applied to be
registered as a bulk manufacturer of the
following basic classes of controlled
substances:
SUPPLEMENTARY INFORMATION:
Controlled substance
Drug code
Cathinone ........................................................................................................................................................................
Mephedrone (4-Methyl-N-methylcathinone) ....................................................................................................................
Lysergic acid diethylamide ..............................................................................................................................................
Tetrahydrocannabinols ....................................................................................................................................................
3,4-Methylenedioxymethamphetamine ............................................................................................................................
Alpha-methyltryptamine ...................................................................................................................................................
Dimethyltryptamine ..........................................................................................................................................................
5-Methoxy-N,N-diisopropyltryptamine .............................................................................................................................
N-Benzylpiperazine ..........................................................................................................................................................
2-(2,5-Dimethoxyphenyl) ethanamine (2C-H) .................................................................................................................
MDPV (3,4-Methylenedioxypyrovalerone) .......................................................................................................................
Methylone (3,4-Methylenedioxy-N-methylcathinone) ......................................................................................................
Heroin ..............................................................................................................................................................................
Normorphine ....................................................................................................................................................................
Norlevorphanol ................................................................................................................................................................
Amphetamine ...................................................................................................................................................................
Nabilone ...........................................................................................................................................................................
Phencyclidine ...................................................................................................................................................................
Cocaine ............................................................................................................................................................................
Codeine ...........................................................................................................................................................................
Ecgonine ..........................................................................................................................................................................
Levorphanol .....................................................................................................................................................................
Meperidine .......................................................................................................................................................................
Methadone .......................................................................................................................................................................
Morphine ..........................................................................................................................................................................
Thebaine ..........................................................................................................................................................................
Levo-alphacetylmethadol .................................................................................................................................................
Noroxymorphone .............................................................................................................................................................
Remifentanil .....................................................................................................................................................................
Sufentanil .........................................................................................................................................................................
Carfentanil .......................................................................................................................................................................
Fentanyl ...........................................................................................................................................................................
khammond on DSKBBV9HB2PROD with NOTICES
The company plans to manufacture
reference standards.
Dated: June 3, 2019.
John J. Martin,
Assistant Administrator.
BILLING CODE 4410–09–P
16:55 Jun 12, 2019
Drug Enforcement Administration
[Docket No. 18–29]
[FR Doc. 2019–12503 Filed 6–12–19; 8:45 am]
VerDate Sep<11>2014
DEPARTMENT OF JUSTICE
Elizabeth C. Korcz, M.D.; Decision and
Order
On March 28, 2018, the Assistant
Administrator, Diversion Control
Division, Drug Enforcement
Administration (hereinafter, DEA or
Jkt 247001
PO 00000
Frm 00081
Fmt 4703
Sfmt 4703
1235
1248
7315
7370
7405
7432
7435
7439
7493
7517
7535
7540
9200
9313
9634
1100
7379
7471
9041
9050
9180
9220
9230
9250
9300
9333
9648
9668
9739
9740
9743
9801
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Government), issued an Order to Show
Cause (hereinafter, OSC) to Elizabeth C.
Korcz, M.D. (hereinafter, Respondent),
who is registered in Hoover, Alabama.
The OSC proposed to revoke
Respondent’s DEA Certificate of
Registration (hereinafter, COR) No.
FK0505428, pursuant to 21 U.S.C.
§§ 823(f) and 824(a)(3), on the ground
that she does not have authority to
handle controlled substances in
E:\FR\FM\13JNN1.SGM
13JNN1
]]>Agencies
[Federal Register Volume 84, Number 114 (Thursday, June 13, 2019)]
[Notices]
[Pages 27658-27659]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-12504]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Registration
ACTION: Notice of registration.
-----------------------------------------------------------------------
SUMMARY: The registrant listed below has applied for and been granted a
registration by the Drug Enforcement Administration (DEA) as a bulk
manufacturer of a basic class of schedule II controlled substances.
SUPPLEMENTARY INFORMATION: The company listed below applied to be
registered as a bulk manufacturer of a basic class of schedule II
controlled substances. Information on a previously published notice is
listed below. No
[[Page 27659]]
comments or objections were submitted for the notice.
------------------------------------------------------------------------
Company FR docket Published
------------------------------------------------------------------------
Navinta, LLC.................... 84 FR 5498..... February 21, 2019.
------------------------------------------------------------------------
The DEA has considered the factors in 21 U.S.C. 823(a) and
determined that the registration of this registrant to manufacture the
applicable basic class of controlled substances is consistent with the
public interest and with United States obligations under international
treaties, conventions, or protocols in effect on May 1, 1971. The DEA
investigated the company's maintenance of effective controls against
diversion by inspecting and testing the company's physical security
systems, verifying the company's compliance with state and local laws,
and reviewing the company's background and history.
Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21
CFR 1301.33, the DEA has granted a registration as a bulk manufacturer
to the above listed company.
Dated: June 3, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019-12504 Filed 6-12-19; 8:45 am]
BILLING CODE 4410-09-P
